Print
Email
Print Edition StoriesMonday, August 10, 2009
EMD Serono teams with Texas cancer center
By Mass High Tech staff
MHT's Marc Songini: Researchers focus on macular degeneration
MHT's Marc Songini: RI plans launch of cord blood center
Rodney Brown on NECN: Hacking into medical devices
EMD Serono Inc., a Rockland-based biopharmaceutical firm, has joined The University of Texas M.D. Anderson Cancer Center in forming a three-year, non-exclusive collaboration. The agreement is expected to help the company bring its cancer treatments to clinical trial quicker and help the medical center provide new oncology drugs sooner for patients.
No financial terms of the alliance were revealed.
According to a release from the Rockland firm, EMD Serono has not yet decided which of its oncology treatments it will aim for Phase 1 clinical trials through the collaboration, but the company said patient enrollment for the trial would begin this year.
M.D. Anderson Cancer Center is one of 40 cancer centers designated by the National Cancer Institute.
EMD Serono is a subsidiary of Merck KGaA of Darmstadt, Germany. The company announced plans in March to open a research facility in Cambridge that will accommodate up to 50 scientists. The laboratory space will be used to conduct research in neurobiology, pharmacology and chemistry, and it will operate as a satellite facility to EMD Serono’s Rockland space and Billerica laboratory.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
